


# Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice

Nana Talvard-Balland, ... , Vijay K. Kuchroo, Robert Zeiser

*J Clin Invest.* 2024. <https://doi.org/10.1172/JCI177460>.

Research In-Press Preview Transplantation

## Graphical abstract



Find the latest version:

<https://jci.me/177460/pdf>



## **Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice**

Nana Talvard-Balland<sup>1,2\*</sup>, Lukas M. Braun<sup>1,3\*</sup>, Karen O. Dixon<sup>4,5</sup>, Melissa Zwick<sup>1,3</sup>, Helena Engel<sup>1</sup>, Alina Hartmann<sup>1</sup>, Sandra Duquesne<sup>1</sup>, Livius Penter<sup>6,7</sup>, Geoffroy Andrieux<sup>8</sup>, Lukas Rindlisbacher<sup>9</sup>, Andrea Acerbis<sup>1</sup>, Jule Ehmann<sup>1</sup>, Christoph Köllerer<sup>1</sup>, Michela Ansuinelli<sup>6</sup>, Andres Rettig<sup>1</sup>, Kevin Moschallski<sup>1</sup>, Petya Apostolova<sup>10,11</sup>, Tilman Brummer<sup>10,12,13</sup>, Anna L. Illert<sup>1,10,14,15</sup>, Markus A. Schramm<sup>16</sup>, Yurong Cheng<sup>17</sup>, Anna Köttgen<sup>17</sup>, Justus Duyster<sup>1</sup>, Hans D. Menssen<sup>18</sup>, Jerome Ritz<sup>6</sup>, Bruce R. Blazar<sup>19</sup>, Melanie Boerries<sup>8,10</sup>, Annette Schmitt-Gräff<sup>20</sup>, Nurefsan Sariipek<sup>21</sup>, Peter Van Galen<sup>21</sup>, Joerg M. Buescher<sup>22</sup>, Nina Cabezas-Wallscheid<sup>22</sup>, Heike L. Pahl<sup>1</sup>, Erika L. Pearce<sup>11</sup>, Robert J. Soiffer<sup>6</sup>, Catherine Wu<sup>6</sup>, Luca Vago<sup>23</sup>, Burkhard Becher<sup>9</sup>, Natalie Köhler<sup>1,2\*\*</sup>, Tobias Wertheimer<sup>1,9\*\*</sup>, Vijay K. Kuchroo<sup>4\*\*</sup>, Robert Zeiser<sup>1,10,12\*\*</sup>

\* Co-first authors, \*\* Co-senior authors

<sup>1</sup> Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

<sup>2</sup> CIBSS – Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg Germany

<sup>3</sup> Faculty of Biology, University of Freiburg, Freiburg, Germany

<sup>4</sup> Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital and Harvard Medical School, Boston, MA, USA

<sup>5</sup> Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland

<sup>6</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

<sup>7</sup> Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

<sup>8</sup> Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

<sup>9</sup> Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

<sup>10</sup> German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany

<sup>11</sup> The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

<sup>12</sup> Signalling Research Centres BIOSS and CIBSS – Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany

<sup>13</sup> Institute of Molecular medicine and cell research (IMMZ), Freiburg, Germany

<sup>14</sup> German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany

<sup>15</sup> Department of Internal Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

<sup>16</sup> Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany

<sup>17</sup> Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany

<sup>18</sup> Novartis Pharma, Basel, Switzerland

<sup>19</sup> University of Minnesota, Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, Minnesota, United States 55455

<sup>20</sup> University of Freiburg, Freiburg, Germany

<sup>21</sup> Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA

<sup>22</sup> Max-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

<sup>23</sup> Unit of Immunogenetics, Leukemia Genomics and Immunobiology, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Scientific Institute, Milano, Italy

**Corresponding author:**

Robert Zeiser, MD  
Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, 79106 Freiburg, Germany  
Tel: +49-761-270-34580, Fax: +49-761-270-73570  
robert.zeiser@uniklinik-freiburg.de

**One Sentence Summary:** Specific oncogenic mutations induce TIM-3 ligands which enhances susceptibility of AML to anti-TIM-3 therapy, an intervention that reverses the T cell phenotype and metabolism.

**Word count:** Abstract: 199

**Abstract**

Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting TIM-3 for improving graft-versus-leukemia (GVL) effects. We observed differential expression of TIM-3 ligands when hematopoietic stem cells overexpressed certain oncogenic-driver mutations. Anti-TIM-3 Ab-treatment improved survival of mice bearing leukemia with oncogene-induced TIM-3 ligand expression. Conversely, leukemia cells with low ligand expression were anti-TIM-3 treatment-resistant. *In vitro*, TIM-3 blockade or genetic deletion in CD8<sup>+</sup> T cells (Tc) enhanced Tc activation, proliferation and IFN- $\gamma$  production while enhancing GVL effects, preventing Tc exhaustion and improving Tc cytotoxicity and glycolysis *in vivo*. Conversely, TIM-3 deletion in myeloid cells did not affect allogeneic Tc proliferation and activation *in vitro*, suggesting that anti-TIM-3-treatment-mediated GVL effects are Tc-induced. In contrast to anti-PD-1 and anti-CTLA-4-treatment, anti-TIM-3-treatment did not enhance acute graft-versus-host-disease (aGVHD). TIM-3 and its ligands were frequently expressed in acute myeloid leukemia (AML) cells of patients with post-allo-HCT relapse.

We deciphered the connection between oncogenic mutations found in AML and TIM-3 ligands expression and identify anti-TIM-3-treatment as a strategy to enhance GVL effects via metabolic and transcriptional Tc-reprogramming, without exacerbation of aGVHD. Our findings support clinical testing of anti-TIM-3 Abs in patients with AML relapse post-allo-HCT.

## Introduction

Acute myeloid leukemia (AML) relapse is the main cause of death after allogeneic hematopoietic cell transplantation (allo-HCT) (1). Mechanisms promoting relapse include MHC class II downregulation (2, 3), loss of mismatched HLA (4), immune checkpoint ligand upregulation (3), reduced IL-15 production (5) and leukemia-derived lactic acid release (6) among others (reviewed in (7)). A longstanding approach to address relapse is treatment with cellular therapy such as donor lymphocyte infusions (DLI), either alone or with hypomethylating agents (HMA) (8, 9). A retrospective analysis on response to DLI reported complete response (CR) rates of 17% for patients with AML (10) and another large retrospective, multicenter study reported a 2-year overall survival (OS) upon DLI treatment of 20% versus 9% upon chemotherapy-only treatment (9). These reports indicate that donor T cells (Tc) can exert graft-versus-leukemia (GVL) effects, but also demonstrate the high unmet medical need for therapies that enhance GVL effects. Current pharmacological approaches for prevention and treatment of AML relapse include the use of FMS-like tyrosine kinase 3 (FLT3)-kinase inhibitors (5, 11, 12), immune checkpoint inhibitors (ICIs) (13-17), HMA (8, 18), B-cell lymphoma 2 (BCL-2) inhibitors (19), mouse double minute 2 (MDM2) inhibition (20) and others (21).

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3) has recently emerged as an inhibitory receptor (22, 23), and more broadly, as a marker for Tc dysfunction in cancer (24). It was recently described that TIM-3 may also play an important role in regulating immune responses in solid tumors as evidenced by recent data from mouse models of melanoma (23). In addition to its role in immune cells, TIM-3 is a promising target in AML because it is highly expressed on leukemic stem cells (LSC) (25). Functionally, TIM-3 and its ligand, galectin-9 (Gal-9), induce an autocrine loop that is essential for LSC self-renewal and AML development (26). Additionally, refractoriness to treatment correlated with TIM-3 expression in AML (27). Early clinical trials testing TIM-3 blockade using the humanized IgG4 anti-TIM-3 Ab (sabatolimab, MBG453, Novartis) in combination with decitabine in 60 evaluable patients with AML outside of the allo-HCT setting reported CR rates of 35.3% (28). The contribution of TIM-3 in LSCs contrary to Tc for clinical activity of anti-TIM-3 Abs remains unclear.

Using an anti-TIM-3 blocking Ab, we observed that TIM-3 inhibition enhanced the survival of leukemia-bearing mice post allo-HCT and reduced exhausted TIM-3<sup>+</sup>PD-1<sup>+</sup> Tc frequencies. Importantly, we report that cell specific TIM-3 deletion in CD8<sup>+</sup> Tc (*Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>*) caused enhanced Tc proliferation, activation, effector phenotype and anti-leukemia immunity

## Results

### Differential TIM-3 ligand expression in hematopoietic stem cells (HSCs) upon oncogene activation confers susceptibility to anti-TIM-3 Ab therapy in multiple AML models

We previously reported that the JAK2-V617F oncogenic mutation enhances the expression of the immunosuppressive programmed death-ligand 1 (PD-L1) (29) and sought to investigate connections between oncogenes found in AML and the expression of TIM-3 (encoded by the hepatitis A virus cellular receptor 2 (*Havcr2*) gene) and its ligands. We observed that the TIM-3 ligands Gal-9 (encoded by *Lgals9*) and carcinoembryonic antigen-related cell adhesion molecule 1 (*Ceacam1*) were differentially expressed when compared to empty vector control depending on the oncogene that was introduced into HSCs of BALB/c mice, with FLT3-ITD showing the greatest upregulation of both ligands. c-KIT-D816V oncogenic-driver mutation led to a significant increase of *Lgals9* in HSCs (**Figure 1A, B**). Conversely, we found no association between oncogenes and TIM-3 or TIM-3 ligand high-mobility group box 1 (*Hmgb1*) expression (**Suppl. Figure 1A, B**). Consistent with the findings in primary HSCs cells, the transduction of the myeloblast-like murine cell line 32D with FLT3-ITD caused enhanced secretion of Gal-9, while less Gal-9 was secreted upon overexpression of FIP1L1-PDGFR $\alpha$  (**Suppl. Figure 1C**). We then transferred HSCs previously transduced with different oncogenes in mice undergoing allo-HCT and allogeneic Tc transfer and compared the efficacy of anti-TIM-3 treatment after FLT3-ITD or FIP1L1-PDGFR $\alpha$  transgenic (Tg) HSCs injection. Mice were treated *i.p.* every 3 days from day 7 to day 28 with 150 $\mu$ g of anti-TIM-3 or isotype Ab. Anti-TIM-3 treatment was efficient in mice undergoing allo-HCT carrying FLT3-ITD Tg HSCs or c-KIT-D816V Tg HSCs but not in mice carrying FIP1L1-PDGFR $\alpha$  Tg HSCs (**Figure 1C-E**). We observed a higher expression of TIM-3 ligands in FLT3-ITD and c-KIT-D816V Tg HSCs compared to FIP1L1-PDGFR $\alpha$  Tg HSCs, which is in agreement with the concept that anti-TIM-3 therapy sensitivity is associated with the expression of TIM-3 ligands.

TIM-3, Gal-9 and CEACAM1 expression levels were increased on CD8<sup>+</sup> Tc at days 17 and 24 in mice injected with FLT3-ITD MLL-PTD AML cells and undergoing allo-HCT with allogeneic Tc transfer compared to untreated control mice (**Suppl. Figure 1D**). This increase likely reflects the activation of allo-reactive T cells. Conversely, gene expression levels of *Havcr2* and *Ceacam1* did not differ on leukemia cells at different time points after allo-HCT as compared to untreated controls. *Lgals9* gene expression was only increased on day 10 after allo-HCT (**Suppl. Figure 1E**).

We further tested the effect of anti-TIM-3 treatment on the GVL effect in additional models using WEHI-3B AML and the previously described FLT3-ITD MLL-PTD driven AML model (5). In all models, donor Tc are infused two days after allo-HCT to reproduce clinical conditions where DLI is administered during low leukemia burden, as shown previously (5, 20). FLT3-ITD MLL-PTD driven AML cells exhibited higher TIM-3 and ligand expression compared to WEHI-

3B AML cells (**Figure F-I**). Anti-TIM-3 treatment improved the survival in both models, with a more prominent effect observed in FLT3-ITD MLL-PTD driven AML, consistent with previous observations (**Figure 1J, K**). Notably, mice treated with anti-TIM-3 Ab without allogeneic Tc transfer were not protected from FLT3-ITD MLL-PTD driven AML (**Figure 1J**) indicating that anti-TIM-3 Ab requires allo-HCT to exert its effects. Anti-TIM-3 treatment also reduced the leukemia burden in FLT3-ITD MLL-PTD driven AML, as evidenced by decreased AML cell frequency in the bone marrow (BM) at day 23 post allo-HCT (**Figure 1L**). Additionally, mice treated with anti-TIM-3 Ab in the absence of allo-HCT were not protected from FLT3-ITD MLL-PTD driven AML (**Suppl. Figure 2A**), supporting the hypothesis that anti-TIM-3 Ab has no direct cytotoxic effect against AML cells but requires allo-HCT. These results highlight that oncogene-driven expression of TIM-3 and its ligands contributes to disease progression and targeting TIM-3 in the presence of donor allogeneic T cells enhances the GVL effect.

### **Anti-TIM-3 Ab treatment after allo-HCT reduces Tc exhaustion, increases glycolytic capacity of Tc and enhances immune responses**

Since Ab dependent cell-mediated cytotoxicity (ADCC) of the anti-TIM-3 Ab on AML cells was unlikely based on the lack of efficacy against AML cells *in vivo* in the absence of Tc (**Figure 1J**), we investigated the effect of anti-TIM-3 Ab treatment on Tc phenotype in both WEHI-3B and FLT3-ITD MLL-PTD AML models. Tc exhaustion, characterized by the co-expression of PD-1 and TIM-3, has been observed in AML patients relapsing after allo-HCT (30). Using WEHI-3B cells with allo-HCT and Tc transfer followed by anti-TIM-3 or isotype Ab treatment, we found a lower frequency of exhausted TIM-3<sup>+</sup>PD-1<sup>+</sup> donor Tc in CD4<sup>+</sup> and CD8<sup>+</sup> Tc subsets, in the spleen and in the BM isolated on day 23 post allo-HCT, upon anti-TIM-3 treatment compared to isotype Ab treatment (**Figure 2A, B, Suppl. Figure 3A-C**). Importantly, this reduction in TIM-3<sup>+</sup> Tc was not due to steric hindrance by the anti-TIM-3 blocking Ab, as the antibodies used for flow cytometry (FC) detection recognize different epitopes, and TIM-3 staining was unaffected by anti-TIM-3 Ab treatment (**Suppl. Fig. 3D, E**). To extend our analysis of Tc exhaustion, we conducted high-resolution spectral FC-based analysis on Tc isolated from spleens at day 23 post allo-HCT in FLT3-ITD MLL-PTD AML-bearing mice. The analysis revealed several CD4<sup>+</sup> and CD8<sup>+</sup> Tc subsets (**Figure 2C, Suppl. Figure 4A**). By investigating both phenotypic and functional markers, we observed that anti-TIM-3 Ab treatment profoundly remodeled both CD4<sup>+</sup> and CD8<sup>+</sup> Tc subsets when compared to isotype Ab treatment. Notably, we found an increased expression of granzyme B in CD8<sup>+</sup> effector Tc subset upon anti-TIM-3 Ab, as well as an increased expression of CD38 and the ectonucleoside triphosphate diphosphohydrolase-1 (CD39) in precursor exhausted CD8<sup>+</sup> Tc (**Figure 2D, E**), which have been described as tumor-specific CD8<sup>+</sup> Tc that exhibit potent anti-tumor activity against different solid cancers (31-34). Following our previous work showing that reduced glycolytic

activity of Tc is associated to impaired GVL effects (6), we next utilized a single-cell FC-based assay to measure the metabolic response in donor Tc by quantifying protein synthesis levels across different immune cells (35). Tc were isolated from spleens of FLT3-ITD MLL-PTD AML-bearing mice post allo-HCT and Tc transfer, because of the improved survival of anti-TIM-3 Ab-treated mice in this model (**Figure 1J**). We observed a higher glycolytic capacity of CD4<sup>+</sup> and CD8<sup>+</sup> Tc upon anti-TIM-3 Ab treatment compared to isotype Ab treatment (**Figure 2F, G**). Additionally, non-targeted metabolomics analysis using liquid chromatography–mass spectrometry (LC-MS) revealed elevated levels of all identified members of the Kyoto Encyclopedia of Genes and Genomes (KEGG) module "glycolysis" in Tc from anti-TIM-3 Ab-treated mice (**Figure 2H**). The analysis of the 10 most significantly enriched pathways revealed an enrichment of the pathway "glycolysis and gluconeogenesis" in Tc isolated from anti-TIM-3 Ab compared to isotype-treated mice (**Suppl. Figure 4A, B**). Taken together, these findings indicate that anti-TIM-3 treatment enhances glycolytic activity in Tc following allo-HCT in leukemia-bearing mice.

Using high-dimensional spectral FC, we next examined the impact of anti-TIM-3 Ab treatment on the myeloid lineage phenotype in FLT3-ITD MLL-PTD AML-bearing mice that had undergone allo-HCT and Tc transfer on day 2 after allo-HCT (**Figure 2I**). Analysis of the spleen at day 23 post allo-HCT revealed a decreased frequency of leukemic blasts, in line with a more potent GVL effect, and a higher frequency of neutrophils upon anti-TIM-3 treatment (**Figure 2K, L**). Consistent with a potential role for neutrophils in ICI-mediated GVL effects, recent evidence has suggested that neutrophils contribute to ICI-induced anti-tumor immune responses (36, 37). Additionally, we found an increased frequency of type-1 conventional DCs (cDC1s) and macrophages upon anti-TIM-3 compared to the isotype Ab treatment (**Figure 2M, N**). cDC1s have been described to provide an essential niche to promote memory precursor T cell maintenance and differentiation in the context of anti-PDL-1 therapy (38). Furthermore, we found that the expression of TIM-3 and Gal-9 was significantly enriched in distinct myeloid cell types upon anti-TIM-3 treatment. Notably, expression of TIM-3 was increased in cDC1s and macrophages, while monocytes and macrophages were enriched for Gal-9 (**Suppl. Figure 4B**).

Consistent with the effects of anti-TIM-3 treatment observed *in vivo*, we observed similar effects following *in vitro* anti-CD3/CD28-mediated Tc activation. When the isotype Ab was added to the culture, more than 30% of CD4<sup>+</sup> and CD8<sup>+</sup> Tc subsets displayed a phenotype of exhaustion (based on the co-expression of PD-1 and TIM-3 on Tc) after 14 days of culture (**Figure 3A**). Consistent with our *in vivo* studies, addition of anti-TIM-3 Ab *in vitro* resulted in reduced frequencies of exhausted Tc in both CD4<sup>+</sup> and CD8<sup>+</sup> subsets (**Figure 3A-E**). Additionally, we observed a decreased expression of the exhaustion-associated transcription

factor thymocyte selection-associated HMG BOX (TOX) in CD4<sup>+</sup> and CD8<sup>+</sup> Tc when the anti-TIM-3 Ab was added to the culture (**Figure 3F-I**).

These findings indicate that anti-TIM-3 Ab treatment induces several changes in both Tc and myeloid cell populations. We found phenotypic features of Tc exhaustion to be reduced *in vitro* and *in vivo*. Accordingly, we observed increased effector functions in different Tc subsets *in vivo*, which is in line with a more effective elimination of AML blasts.

### **Genetic TIM-3 deletion in CD8<sup>+</sup> Tc enhances Tc activation, proliferation and IFN- $\gamma$ production as well as GVL effects**

Since the anti-TIM-3 Ab will block TIM-3 on multiple cell types, we next used TIM-3 conditional knockout mice (*Havcr2<sup>cko</sup>*) generated previously via Cre/lox based gene deletion (23), to identify the cell types relevant for the anti-TIM-3 Ab-mediated effects. To test the role of TIM-3 for allo-antigen driven Tc activation, Tc were exposed *in vitro* to allogeneic stimulating Tc-depleted PBMCs. We observed that specific TIM-3 deletion in CD8<sup>+</sup> Tc (*Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>*) caused increased proliferation compared to *Havcr2<sup>fl/fl</sup>* Tc (**Figure 4A**). Conversely, TIM-3 deletion in all DCs (*Havcr2<sup>fl/fl</sup>;Cd11c<sup>cre/+</sup>*) or conventional DC (*Havcr2<sup>fl/fl</sup>;Zbtb46<sup>cre/+</sup>*) subsets used for allogeneic stimulation did not affect Tc proliferation (**Suppl. Figure 6A, B**). Additionally, upon co-culture with allogeneic stimulating cells, *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* Tc exhibited elevated expression of activation markers CD25 and CD69 compared to *Havcr2<sup>fl/fl</sup>* Tc (**Figure 4B-E**), which is consistent with the increased proliferation of CD8<sup>+</sup> Tc. In contrast, TIM-3 deficiency in the stimulating cells did not induce CD25 and CD69 upregulation in Tc (**Suppl. Figure 6C-F**).

To analyze the contribution of recipient DCs, we pre-treated the mice with anti-TIM-3 Ab at day -4 and day -1 before allo-HCT. The Ab would bind to the recipient's APCs and therefore induce blockade of TIM-3 on these. However, we found no survival advantage in mice pre-treated with anti-TIM-3 Ab before allo-HCT (**Suppl. Figure 6G**), confirming our hypothesis that anti-TIM-3 Ab treatment acts on allogeneic Tc to reinvigorate CD8<sup>+</sup> Tc and thus reduce Tc exhaustion.

Consistent with enhanced activation, IFN- $\gamma$  production was increased in *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* Tc compared to *Havcr2<sup>fl/fl</sup>* Tc upon stimulation with allogeneic APC *in vitro* for 2 days (**Figure 4F**) or 4 days (**Figure 4G**). Next, we aimed to investigate Tc function *in vivo* by injecting both TIM-3 conditional knockout (*Havcr2<sup>cko</sup>*, C57BL/6) BM and Tc into WEHI-3B-bearing allogeneic BALB/c recipient mice. We observed that transfer of Tc caused improved survival of AML-bearing mice after allo-HCT when TIM-3 was deleted in CD8<sup>+</sup> Tc compared to *Havcr2<sup>fl/fl</sup>* Tc (**Figure 4H**). Moreover, using *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* mice as donors for allogeneic BM and Tc led to improved survival of AML-bearing mice after allo-HCT compared to *Havcr2<sup>fl/fl</sup>* Tc (**Figure 4I**). Supporting our findings *in vivo*, *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* Tc exhibited higher cytotoxic capacity against WEHI-3B cells compared to *Havcr2<sup>fl/fl</sup>* Tc *in vitro* (**Figure 4J**).



We analyzed the phenotype of Tc from the spleens of *Havcr2<sup>cko</sup>* mice under steady state conditions and observed no difference with respect to CD4<sup>+</sup> and CD8<sup>+</sup> Tc frequencies (**Suppl. Figure 7A-B**) and phenotype (**Suppl. Figure 7C**) between the three different genotypes.

We assessed the development of acute graft-versus-host-disease (aGVHD) by histological scoring of the liver, small intestines (SI) and colon and found no significant difference between mice that had received *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* or *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* compared to *Havcr2<sup>fl/fl</sup>* Tc (**Suppl. Figure 8A-C**). Additionally, we found a reduction of the leukemia burden in allo-HCT mice that had received *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* or *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* Tc compared to *Havcr2<sup>fl/fl</sup>* Tc (**Suppl. Figure 8D**). We also observed a reduced frequency of TOX<sup>+</sup> cells and an increased frequency of the transcription factor 7 (TCF-7<sup>+</sup>) cells among CD8<sup>+</sup> Tc in allo-HCT mice that had received Tc isolated from *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* or *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* mice compared to *Havcr2<sup>fl/fl</sup>* mice (**Suppl. Figure 8E-G**). TCF-7 is a transcription factor known to be critical for the generation of the CD8<sup>+</sup> Tc memory response (39). Accordingly, we observed a significant expansion of phenotypic CD8<sup>+</sup> effector memory Tc, as seen by the increased frequency of IFN-γ<sup>+</sup> TNFα<sup>+</sup> cells among TCF-7<sup>+</sup> CD8<sup>+</sup> Tc in allo-HCT mice that had received *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* or *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* Tc compared to *Havcr2<sup>fl/fl</sup>* Tc (**Suppl. Figure 8H**). These results suggest a more efficient and sustainable CD8<sup>+</sup> Tc immune response, which could explain the benefit in the survival outcomes observed when TIM-3 is deleted in all donor Tc compared to the deletion of TIM-3 in CD8<sup>+</sup> Tc only.

Overall, deleting TIM-3 in both CD4<sup>+</sup> and CD8<sup>+</sup> Tc has an additive effect compared to deletion in CD8<sup>+</sup> Tc alone, potentially because CD4<sup>+</sup> Tc support CD8<sup>+</sup> Tc function by producing IFN-γ. TIM-3 may inhibit CD4<sup>+</sup> Tc activity. Conversely, deletion of TIM-3 in CD4<sup>+</sup> Tc may lead to their consecutive activation, which may further enhance CD8<sup>+</sup> Tc effector function against AML cells.

Taken together, these results indicate that genetic deletion of TIM-3 in CD8<sup>+</sup> Tc enhances Tc activation, proliferation and IFN-γ production *in vitro*. *In vivo* deletion of TIM-3 in CD8<sup>+</sup> Tc or all Tc improves GVL effects. Conversely, TIM-3 deletion in DCs did not affect allogeneic Tc responses *in vitro*.

### **Single-cell RNA sequencing (scRNA-seq) reveals that genetic TIM-3 deletion in CD8<sup>+</sup> Tc expands CD8<sup>+</sup> stem-like Tc and promotes features of effector Tc**

To decipher the mechanism underlying the enhanced GVL effect seen when deleting TIM-3 in CD8<sup>+</sup> Tc, we performed scRNA-seq on donor *Havcr2<sup>fl/fl</sup>* and *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>* Tc isolated from the spleen of WEHI-3B-bearing BALB/c recipient mice. We prepared scRNA-seq libraries from

CD3<sup>+</sup> Tc for 4 samples (n=2 *Havcr2<sup>fl/fl</sup>* and n=2 *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>*). Data integration revealed 21 distinct clusters (**Suppl. Figure 9A**) before exclusion of non-CD3<sup>+</sup> cells (**Suppl. Figure 9B**). The analysis was then sub-clustered into CD4<sup>+</sup> and CD8<sup>+</sup> Tc (**Suppl. Figure 9C**).

Clustering analysis of CD8<sup>+</sup> Tc revealed 10 populations of Tc, including 2 clusters of progenitor cells (cluster 4 and cluster 5), 5 subsets of effector Tc (cluster 0, 1, 2, 3, 8 and 9) and 3 populations of exhausted Tc (clusters 2, 6 and 7) (**Figure 5A**). The top 6 genes in each cluster of CD8<sup>+</sup> Tc is shown in **Suppl. Figure 10A**. All clusters of exhausted Tc expressed characteristic genes, including those encoding for TOX (40), PD-1 and Lymphocyte-activation gene 3 (LAG-3). However, in contrast to cluster 6 and cluster 7, cells in cluster 2 also expressed high levels of the genes encoding for the transcription factors Eomesodermin (Eomes) and nuclear receptor 4A2 (Nr4a2), which have been reported to be strongly associated with exhaustion (41). Moreover, cluster 6 and cluster 7 were the only clusters to express Tcf7 and the signaling lymphocytic activation molecule family member 6 (Slamf6), allowing us to identify cluster 6 and 7 as precursor exhausted (T<sub>PEX</sub>) and cluster 2 as terminally exhausted (T<sub>TEX</sub>) CD8<sup>+</sup> Tc (**Figure 5B**; **Suppl. Figure 10A**). T<sub>PEX</sub> are non-fully functional CD8<sup>+</sup> Tc displaying a stem-like profile that persist long-term and differentiate into T<sub>TEX</sub> subset. Consequently, T<sub>PEX</sub> have been described to better control tumor growth than T<sub>TEX</sub> in several solid cancers. Additionally, it has been shown that Tcf7 and Slamf6 expressing CD8<sup>+</sup> Tc contribute to ICI-mediated anti-tumor immune responses (42-44). All clusters were represented in both *Havcr2<sup>fl/fl</sup>* and *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* conditions, albeit in different proportions (**Figure 5C**, **Suppl. Figure 10B-C**) and the number of cells that are present in each CD8<sup>+</sup> Tc cluster is shown in **Suppl. Table 1**.

In particular, cluster 6 containing T<sub>PEX</sub> cells was more abundant in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* Tc compared to *Havcr2<sup>fl/fl</sup>* Tc. In contrast cluster 2, which represents T<sub>TEX</sub> cells, was less abundant in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* Tc. Additionally, cluster 8 and 9, identified as short-term effector CD8<sup>+</sup> Tc, were less abundant in *Havcr2<sup>fl/fl</sup>* Tc. (**Figure 5C**). Moreover, Tc in cluster 6 expressed higher levels of Tcf7 and Slamf6 in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* Tc (**Figure 5D**) and cluster 7 was strongly enriched for a transcriptomic signature of memory precursor Tc (**Figure 5E**), indicating an enriched T<sub>PEX</sub> signature for these 2 clusters of CD8<sup>+</sup> Tc in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* Tc. Additionally, we performed gene-set-enrichment in CD8<sup>+</sup> Tc clusters, revealing significant transcriptional differences between *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* and *Havcr2<sup>fl/fl</sup>* groups (**Suppl. Figure 10D**). In particular, T<sub>PEX</sub> subsets in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* group showed enrichment in the “IL-2/Stat5 signaling pathway” and “inflammatory response”. Notably, cluster 7 (T<sub>PEX</sub> subset) was enriched for the “Wnt/β-catenin signaling” pathway, crucial for Tc differentiation, effector functions, and migration (45). Furthermore, several studies have described the importance of Wnt/β-catenin signaling in the activation and maintenance of T<sub>PEX</sub>, which display indispensable antitumor capacities (46, 47), confirming an enriched signature for memory Tc in the *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* group. These results

demonstrate that TIM-3 deletion in CD8<sup>+</sup> Tc promotes the expansion of polyfunctional T<sub>PEX</sub> and effector Tc, contributing to the enhanced GVL effects observed in mice receiving *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* Tc compared to those receiving *Havcr2<sup>fl/fl</sup>* Tc.

Within CD4<sup>+</sup> Tc subclusters, we identified 6 distinct cell types, including a Treg cluster (cluster 5), and 5 clusters of effector/memory CD4<sup>+</sup> Tc (**Suppl. Figure 11A, B**). Clusters 0 and 2, containing effector memory/effector Tc (Tem/Teff), were more abundant in TIM-3-deficient CD8<sup>+</sup> Tc. Cluster 4, identified as resident-memory-like CD4<sup>+</sup> Tc, was more abundant in *Havcr2<sup>fl/fl</sup>* Tc (**Suppl. Figure 11C**). Cluster 1, characterized by high transcription Factor 7 (Tcf7) and Slamf6 expression, defined precursor effector memory Th1 cells, required for long-term and heightened anti-tumor immunity (48), including in the context of allo-HCT (49). We found that cells in cluster 1 exhibited an enriched transcriptomic signature for memory precursor Tc in the *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* group (**Suppl. Figure 11D**). Additionally, cluster 3 was strongly enriched for a transcriptomic signature of early activated cytotoxic CD4<sup>+</sup> Tc in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* Tc (**Suppl. Figure 11E**). The top 6 genes in each cluster of CD4<sup>+</sup> Tc is shown in **Suppl. Figure 12A**. All clusters were represented in both *Havcr2<sup>fl/fl</sup>* and *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* Tc (**Suppl. Figure 11C, Suppl. Figure 12B-C**) and the number of cells that are present in each CD4<sup>+</sup> Tc cluster is shown in **Suppl. Table 1**. Additionally, gene-set enrichment analysis in CD4<sup>+</sup> Tc clusters revealed enriched signatures for interferon responses and an enriched "inflammatory response" pathway in the *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* group, indicating a more efficient immune response. (**Suppl. Figure 12D**). These results demonstrate that TIM-3 deletion in CD8<sup>+</sup> Tc contributes to the expansion of precursor effector memory Th1-like and early activated cytotoxic CD4<sup>+</sup> Tc subsets, highlighting TIM-3's complex role in Tc subpopulations.

### **Anti-TIM-3 treatment results in immune recall against AML cells without enhancing acute GVHD (aGVHD)**

We assessed the potential of TIM-3 Ab treatment to induce immune memory against AML cells by isolating donor Tc from AML-bearing mice post allo-HCT treated with anti-TIM-3 or isotype Ab. These Tc were transferred into secondary AML-bearing mice post allo-HCT, resulting in improved survival in mice that received Tc from anti-TIM-3-treated recipients compared to isotype-treated mice (**Figure 6A**).

To evaluate the impact of anti-TIM-3 treatment on aGVHD, we examined SI, colon and liver tissues from mice treated with anti-PD-1, anti-cytotoxic T-lymphocyte-associated Protein 4 (anti-CTLA-4) or anti-TIM-3 Abs after allo-HCT. All Abs (150µg) were given daily, from day 1 to day 5. Histopathological analysis revealed increased aGVHD severity in all organs from mice treated with anti-PD-1 or anti-CTLA-4 compared to their respective isotype Abs treatment

(**Figure 6B, C**). Conversely, anti-TIM-3 treatment did not exacerbate aGVHD severity in these organs compared to the isotype Ab (**Figure 6D**).

### **The clinical grade humanized anti-TIM-3 Ab sabatolimab enhances the GVL effect**

To further explore the potential of TIM-3 blockade in improving GVL effects against human leukemia, we used a humanized mouse model. Immunodeficient *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* mice were injected with the human FLT3-ITD mutant AML cell line MOLM-13<sup>luc+</sup> and allogeneic human Tc (18). These *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* mutant mice lack T, B and NK cells and are therefore suitable hosts for transplanted human immune cells. Mice were treated *i.p.* with 150µg of the humanized anti-TIM-3 Ab (MBG453) or vehicle every 3 days from day 7 to day 28. Anti-TIM-3 Ab treatment resulted in improved survival (**Figure 7A**) and reduced leukemia burden, as assessed on day 21 post allo-HCT by luciferase imaging (**Figure 7B, C**) compared to vehicle-treated mice. Additionally, *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* mice receiving CD3-depleted human primary AML blasts and donor Tc from HLA mismatched healthy donors and treated with sabatolimab showed improved survival (**Figure 7D, E**). We also investigated if FLT3-ITD mutational status affects TIM-3. We treated human-derived MOLM-13 cells with different FLT3 inhibitors (Crenolanib, Quizartinib and Tandutinib) to prevent FLT3 signaling and observed a decreased expression of Gal-9, CEACAM1 and TIM-3 in FLT3-ITD mutant AML cells, but not in Kasumi-1 cells (FLT3 WT) (**Figure 7F-I**), indicating that oncogenic FLT3-ITD signaling upregulates TIM-3 and its ligands in human AML.

### **Expression of TIM-3 and its ligands in different cell populations isolated from patients with AML relapse after allo-HCT.**

To clarify if our results in mice could be related to the human context, we evaluated the expression of TIM-3 (*HAVCR2*) and its ligands (*CEACAM1*, *HMGB1*, *LGALS9* and *PTDSS1*) in primary patient samples. First, we interrogated published scRNA-seq datasets of human BM samples in the setting of newly diagnosed AML (50, 51), transplant-naïve (52, 53) or post-transplant AML relapse (53), and physiologic hematopoiesis (50-52, 54). To enable comparison across these datasets, we annotated hematopoietic and immune cells based on a healthy BM reference (**Methods**) (55) (**Figure 8A**). In normal hematopoiesis and in AML, *HAVCR2* expression was detectable in myeloid progenitor cells, Tc and NK cells (56), and all four TIM-3 ligands were expressed by HSC- and progenitor-populations (**Figure 8B, Suppl. Figure 13A**). We found high *HAVCR2* expression in NK cells, in agreement with previous reports (56) which might be particularly relevant for the early post-transplant context, where NK cells are more abundant than in transplant-naïve AML (**Figure 8C**). Additionally, it has been shown that TIM-3 is highly expressed by NK cells in patients with AML, correlating with enhanced effector functions and NK cell cytotoxicity and improved clinical outcome in AML

patients (57). Compared to healthy myelopoiesis, we observed higher expression of *HAVCR2* and *LGALS9* but not *HMGB1* in newly diagnosed AML (**Figure 8D**, **Suppl. Figure 13A**). Expression of *CEACAM1* was found below the detection limit and only detected in 0.4% of the cells (data not shown) (50). Second, we evaluated the expression of TIM-3 and its ligands in human primary AML cells isolated from patients that experienced a relapse after allo-HCT at multiple transplant centers (**Suppl. Table 2**) using bulk RNA-seq. We observed heterogeneous expression of *HAVCR2* and its ligands *LGALS9*, *CEACAM1* and *HMGB1* (**Figure 8E**) as well as variable counts of TIM-3<sup>+</sup> Tc (cells/ $\mu$ L) in peripheral blood (PB) of patients 1, 2 or 3 months after allo-HCT (**Suppl. Figure 13B**). These results may suggest differential therapeutic sensitivity to TIM-3 inhibition.

To understand whether TIM-3 expression impacts survival, we analyzed the probability of survival depending on the level of expression of *HAVCR2* (mean) in bulk RNA-sequencing data derived from published databases on human cells. We defined *HAVCR2* gene expression more than one standard deviation above mean as high expression. We observed that patients with high *HAVCR2* expression in BM cells at diagnosis showed significantly improved survival compared to patients with low *HAVCR2* expression when analyzing the Target-AML cohort (58), comprising 1630 low and 276 high TIM-3 expressing BM patient samples (**Figure 8F**). This pattern was also observed in peripheral blood (**Suppl. Figure 14A**). The improved survival with higher TIM-3 expression may be linked to a high count of TIM-3<sup>+</sup> NK cells, which have the highest TIM-3 levels.

## Discussion

Since relapse of the underlying malignancy is the major cause of death beyond day 100 after allo-HCT (59), novel strategies to prevent or treat relapse are urgently needed. Tc exhaustion and increased immune checkpoint ligand expression have been reported in patients with AML relapse after allo-HCT (3, 30), which supports the use of approaches that target exhausted Tc populations. Prior studies have shown that targeting immune checkpoint molecules using anti-PD-1 and anti-CTLA-4 Abs have clinical activity in a fraction of AML patients after allo-HCT, however aGVHD has limited the use of these antibodies in the patients (13, 14, 60).

In this study, we deciphered the potential of targeting TIM-3 to overcome immune escape and reinvigorate immune cells to enhance anti-leukemia immunity after allo-HCT in AML.

We observed that anti-TIM-3 Ab treatment reduced features of Tc exhaustion and enhanced Tc effector functions, leading to an improved GVL activity in multiple murine and humanized AML models. Specific TIM-3 deletion on CD8<sup>+</sup> Tc allowed us to dissect the mechanism underlying the improvement of GVL effects. We identified two subpopulations of CD8<sup>+</sup> exhausted Tc and found that polyfunctional stem-like T<sub>PEX</sub> cells expanded when TIM-3 was deleted in CD8<sup>+</sup> Tc while cytotoxic but short-lived T<sub>TEX</sub> population remained unchanged, leading to a more effective, robust and durable Tc-mediated immune response. TIM-3 deletion in the CD8<sup>+</sup> Tc subset also affected CD4<sup>+</sup> Tc subpopulations, in particular causing expansion of Th1-like memory CD4<sup>+</sup> Tc, recently described to display improved survival and persistence functions in the context of alloimmunity (49).

TIM-3 is also highly expressed on NK cells. However, its role in modulating NK function remains unclear, particularly in human diseases. The expression of TIM-3 on NK cells has been reported to be associated with both NK activation (61, 62) and dysfunction/exhaustion (63), depending on the cytokine stimulation (64). We observed an increased frequency of TIM-3-expressing NK cells in early post-transplant AML patients, consistent with other studies reporting that high TIM-3 expression on NK cells from AML patients correlates with an enhanced NK cell cytotoxicity and effector functions, and an ultimately improved clinical outcome in AML patients (57).

We also observed a higher frequency of neutrophils within immune cells isolated from leukemia-infiltrated spleens of AML-bearing mice upon anti-TIM-3 Ab treatment, consistent with several recent independent studies showing that neutrophils may contribute to tumor control (36, 37). The authors reported that ICI-therapy exposed neutrophils acquired an IFN- $\gamma$  gene signature suggesting their contribution to the anti-tumor immune responses. Hirschhorn *et al.* identified a distinct anti-tumorigenic neutrophil subset that occurred in ICI-treated mice (36). They described the interaction between Tc mediating the initial anti-tumor immune response and neutrophils that eliminate tumor antigen loss variants (36).

Our study revealed that enhanced anti-tumor immunity upon anti-TIM-3 Ab therapy involves additional indirect immune mechanisms, recently described upon ICI therapy in solid cancers (36, 37).

A major concern when using ICI after allo-HCT is the development of severe aGVHD reported with anti-PD-1 and anti-CTLA-4 therapy (13-16). Consistently, we found that anti-PD-1 and anti-CTLA-4 treatment induced aGVHD in mice. Conversely, we observed no GVHD enhancement when using anti-TIM-3 Ab treatment. This might be because TIM-3 expression is restricted to terminally differentiated Tc (65, 66), which may contribute less to GVHD. However, the absence of GVHD development may be strictly dependent on the specific anti-TIM-3 Ab and the administration schedule. A previous preclinical study by Veenstra et al. (67) using a TIM-3-Ig fusion protein demonstrated that TIM-3 blockade exacerbated aGVHD in mice. Conversely, we treated the mice with an anti-TIM-3 Ab (monoclonal Ab, clone 5D12). Further, the group showed that TIM-3<sup>-/-</sup> mice used as donors led to enhanced aGVHD, whereas we used mice carrying a conditional specific TIM-3 deletion in selected immune subpopulations. Additionally, the number of donor Tc used to induce GVHD was 10 times higher ( $3 \times 10^6$  of purified CD25<sup>-</sup> Tc) compared to our model ( $3 \times 10^5$  pan-Tc). These studies show that usage of TIM-3 Abs requires caution with respect to aGVHD development.

Previous studies suggested that targeting TIM-3 may directly eliminate LSCs via ADCC due to high TIM-3 expression on AML blasts and interruption of the Gal-9 feedback loop by the Ab (25, 26). However, we found that anti-TIM-3 treatment's effectiveness depended on the presence of alloreactive T cells, with no direct effect on AML cells.

Furthermore, our data suggest that specific oncogenic mutations may influence the effectiveness of ICIs against AML post allo-HCT, with TIM-3 blockade potentially benefiting patients with specific mutations and high TIM-3 ligand expression. Following our previous observation that certain oncogenic mutations lead to enhanced expression of inhibitory checkpoint ligands (29), we found that TIM-3 ligands Gal-9 and CEACAM1 were overexpressed in HSCs carrying FLT3-ITD and c-kit-D816V mutations. Treating mice with mutated AML cells using an anti-TIM-3 Ab resulted in a robust response upon anti-TIM-3 treatment, confirming our hypothesis. This highlights the potential for personalized TIM-3 blockade therapy in AML patients, emphasizing the need for innovative clinical study designs that consider leukemia genetics. Taken together, our findings demonstrate that TIM-3 and its ligands contribute to immune evasion, complementing research showing higher Gal9/Tim-3 expression in AML patients who fail chemotherapy (27).

We conducted allo-HCT with donor Tc that recognize foreign MHC on AML cells, mimicking the GVL effect observed in patients. However, besides alloantigen specific immune responses also tumor antigen specific immune responses that are MHC independent may play a role.

Previous studies have demonstrated the potential to target leukemia cells using leukemia reactive T cell lines (68).

Our preclinical work in part motivated a phase Ib/II, open-label, multicenter clinical trial using sabatolimab monotherapy for patients with molecular relapse after allo-HCT (EUDRACT number 2020-000869-17, ClinicalTrials.gov Identifier: NCT04623216) which no GVHD was observed in the 21 patients enrolled in the trial to date (69).

In summary, our study elucidates the link between oncogenic mutations in AML and TIM-3 ligand expression and identify anti-TIM-3 treatment as a strategy to enhance the GVL effect through metabolic and transcriptional reprogramming of Tc after allo-HCT. These findings support the ongoing clinical evaluation of sabatolimab for AML patients following allo-HCT.



## Methods

### Sex as a biological variable

Our study examined male and female animals, and similar findings are reported for both sexes.

### Study design

The objective of this study was to target TIM-3 to enhance anti-leukemia immune responses after allo-HCT. We employed well-established allogeneic and xenogeneic GVL and aGVHD murine models to investigate the role of TIM-3 and its ligands. We utilized mouse anti-TIM-3 Ab (clone 5D12) or isotype Ab (mIgG1), clinical grade anti-human TIM-3 Ab MBG453 (Sabatolimab) or vehicle (5% glucose solution) or conditional knock-out (*Havcr2<sup>cko</sup>*) mice. Anti-TIM-3 Abs (5D12 and MBG453) and isotype Ab were provided by Novartis Institutes of Biomedical Research (Cambridge, US).

All Abs used for FC are summarized in **Suppl. Table 3 and 4**.

### Animal models

C57BL/6 (H-2Kb) and BALB/c (H-2Kd) mice were purchased from Janvier Labs (France). *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* mice were obtained from the local stock at the animal facility of Freiburg University Medical Center. C57BL/6 *Havcr2<sup>cko</sup>* mice (*Havcr2<sup>fl/fl</sup>*, *Havcr2<sup>fl/fl</sup>;E8<sup>cre/+</sup>*, *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>*, *Havcr2<sup>fl/fl</sup>;Cd11c<sup>cre/+</sup>* and *Havcr2<sup>fl/fl</sup>;Zbtb46<sup>cre/+</sup>*) were provided by Vijay K. Kuchroo (Boston, MA, US) and were described previously (23). 7 to 12 weeks old mice and female or male donor/recipient pairs were used.

### Cell lines

WEHI-3B cells (ACC 26), MOLM-13 cells (ACC 554) and 32D cells (ACC 411) were obtained from DSMZ. MOLM-13 were then transduced in our lab to express luciferase. Kasumi-1 cells were provided by Prof. Michael Lübbert (Freiburg, Germany). Cell lines were routinely tested for Mycoplasma contamination and authenticated by STR profiling. FLT3-ITD MLL-PTD splenocytes were provided by Bruce R. Blazar (Minnesota, US).

### Statistics

The comparison between quantitative and qualitative variables was done using a 2-tailed Student's t test (parametric) or the Mann-Whitney U test (nonparametric). Variance analysis was done using a 1-way ANOVA (parametric) or Kruskal-Wallis (nonparametric) test. A Cox model was applied for survival analysis. For spectral FC analysis, differentially expressed proteins were tested with moderated t-test of limma. Concerning bar diagrams representing the frequency of the different Tc clusters, adjusted P-values were calculated using Fisher's test. Patients were stratified based on high versus low expression of HAVCR2 gene

expression in PB. Gene expression more than one standard deviation above the mean was considered as high expression. Statistical significance was set at a P-value of less than 0.05. All statistical analyses used are described in the corresponding figure legends.

## **Study approval**

### **Human samples**

Human PB and/or BM samples were derived from AML patients treated at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, after prior informed consent. Human PB was collected in sterile EDTA tubes and PBMC were isolated using gradient centrifugation (Pancoll Human). Written informed consent was obtained from each patient and analysis of human data was carried out in compliance with relevant ethical regulations. The characteristics of patients are listed in the **Suppl. Table 2**.

### **Mice**

Animal protocols were approved by the animal ethics committee Regierungspräsidium Freiburg, Freiburg, Germany (protocol numbers: G23/049, G20/103, G20/75 and G20/096).

### **Data availability**

The scRNA-seq data are deposited in the database GEO repository under the GEO accession number GSE242334.

The procedures used for the analysis of human scRNA sequencing datasets are described on [https://github.com/petervangalen/reanalyze-aml2019/blob/main/230830\\_Heatmaps\\_Zeiser.R](https://github.com/petervangalen/reanalyze-aml2019/blob/main/230830_Heatmaps_Zeiser.R).

All raw data are provided in the Supporting Data Values file.

### **Additional experimental procedures**

All other materials and methods are described in the Supplementary Methods.

### **Conflict of interest statement:**

R.Z. reports honoraria from Novartis, MNK, Sanofi, Incyte, and VectivBio outside the submitted work. J.R. received research funding from Kite/Gilead, Novartis and Oncternal Therapeutics and serves on advisory boards for Akron Biotech, Clade Therapeutics, Garuda Therapeutics, LifeVault Bio, Novartis, Smart Immune and TScan Therapeutics. B.R.B. receives remuneration as an advisor to Magenta Therapeutics, BlueRock Therapeutics, Incyte, GentiBio, Legend Biotech; research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre Biopharmaceuticals, and Carisma Therapeutics, Inc.; and is a cofounder of Tmunity Therapeutics. V.K.K. has an ownership interest in and is a member of the scientific advisory board for Tizona Therapeutics, Bicara Therapeutics, Compass Therapeutics, Larkspur

Biosciences and Trishula Therapeutics. K.O.D and V.K.K. are named inventors on patents related to TIM-3. H.D.M. reports employment with Novartis AG, Basel, Switzerland. Novartis is the owner of the investigational compound sibatolimab that has been studied in context of the work described in this article. No disclosures were reported by the other authors. All other authors have declared no conflict of interest.

#### **Grant support:**

This study was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – SFB-1479 – Project ID: 441891347 (to R.Z., T.B., M.B., A.K., and N.K.), CRC1453 (Project ID 431984000-S1 to M.B. and A.K.), CRC1160 (Project ID 256073931-Z02 to M.B.), SFB TRR167 (to R.Z., M.B. and A.L.I.), Project-ID 259373024 – TRR 167, the European Union: ERC-2022-ADG Project 101094168- AlloCure (ERC Advanced grant to R.Z.), ERA-NET Transcan SmartCAR-T and PIXEL (JTC2021) to R.Z., EU project: Project 101119855 — exTra, by the Germany's Excellence Strategy (CIBSS – EXC-2189 – Project ID 390939984 to N.T-B., A.K., N.K. and R.Z.), the Jose-Carreras Leukemia foundation grant number DJCLS 09R/2022 (R.Z.), and by the Else Kröner-Fresenius-Stiftung (2019\_A74 to N.K.), Leukemia and Lymphoma society (award number 7030-23 to R.Z., L.V. and C.W.). V.K.K. was supported by the National Institutes of Health (R01 AI144166, R01 CA282794, P01 AI056299, P01 AI039671, P01 CA236749). K.O.D. was supported by the Swiss National Science Foundation (PZ00P3\_202029) and European Commission, Excellent Science H2020 (10130984). M.B. was supported by the German Federal Ministry of Education and Research (BMBF) within the Medical Informatics Funding Scheme (MIRACUM, FKZ 01ZZ1606A-H, PM<sup>4</sup>Onco FKZ 01ZZ2322 to M.B. and EkoEstMed–FKZ 01ZZ2015 to G.A.), DKTK (German Cancer Consortium) project NoviCARAZA (to R.Z.). L.P. is a Scholar of the American Society of Hematology, a BIH Charité Digital Clinician Scientist and is supported by the Max-Eder program of the German Cancer Aid. B.R.B. was supported in part by NIH (R01 155114; 2P01 CA065493; P01 AI056299 and R37 AI34495). E.L.P. is supported by the NIH (R01AI156274). T.W. is supported by a Walter-Benjamin fellowship of the DFG.

#### **Author contributions:**

N.T-B. and L.M.B. developed the overall concept of the study, performed the experiments, analyzed all data, generated figures and wrote the manuscript. N.T-B and L.M.B made important contributions, and first authorship order was based on the amount of work each first author contributed to the study. K.O.D. and V.K.K. provided the Havcr2<sup>cko</sup> mice and helped to analyze the scRNA-seq results. M.Z. helped to perform scRNA-seq experiment. A.H helped to prepare histology slides. T.W. and L.R. generated and analyzed spectral FC data. L.P., M.A., N.S. and P. VG. provided and analyzed human scRNA-seq datasets. G.A., M.B., N.K. analyzed

the scRNA-seq data. A.R. collected patient samples, helped with experiments and helped to write the manuscript. K.M. reanalyzed published human databases. P.A., J.M.B., N.C-W. and E.L.P. helped to perform the LC-MS experiment and helped with the analysis. Y.C. and A.K. helped with the analysis of the metabolomics. P.A. helped to develop the concept for single cell FC-based metabolism technology. S.D., C.K. and H.E. helped with experiments. M.S., T.B., A.L.I. and J.D. provided plasmids and helped with experimental design. A.S-G. performed histopathological analyses. H.P. helped with experimental design. L.V. analyzed human data from databases. H.D.M. provided essential reagents (MBG453 sabatolimab). B.R.B, C.W., R.J.S., N.K., T.W. and V.K.K. contributed to critical analysis of the data. R.Z. developed the overall concept of the study, supervised the experiments, analyzed data and wrote the first version of the manuscript.

**Acknowledgements:**

The authors thank the Lighthouse Core Facility for their support with FACS and qPCR. Lighthouse Core Facility is funded in part by the Medical Faculty, University of Freiburg (Project Numbers 2021/A2-Fol; 2021/B3-Fol) and the DFG (Project Number 450392965). The authors thank Barbara Sauer for her help with histology sample preparation.

## References:

1. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. *Biol Blood Marrow Transplant.* 2020;26(8):e177-e82.
2. Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klcio JM, Helton NM, O'Laughlin M, Fronick CC, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *N Engl J Med.* 2018;379(24):2330-41.
3. Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M, Spinelli O, Greco R, Crucitti L, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. *Nat Med.* 2019;25(4):603-11.
4. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. *N Engl J Med.* 2009;361(5):478-88.
5. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Muller TA, Hanke K, Taromi S, Apostolova P, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nat Med.* 2018;24(3):282-91.
6. Uhl FM, Chen S, O'Sullivan D, Edwards-Hicks J, Richter G, Haring E, Andrieux G, Halbach S, Apostolova P, Buscher J, et al. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. *Sci Transl Med.* 2020;12(567).
7. Zeiser R, and Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. *Blood.* 2019;133(12):1290-7.
8. Poire X, Graux C, Ory A, Herman J, Baron F, Schoemans H, Lewalle P, De Becker A, Deeren D, Berneman Z, et al. Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). *Bone Marrow Transplant.* 2022;57(1):116-8.
9. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gurman G, Maertens J, Bordigoni P, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. *J Clin Oncol.* 2007;25(31):4938-45.
10. Roux C, Tifratene K, Socie G, Galambrun C, Bertrand Y, Rialland F, Jubert C, Pochon C, Paillard C, Sirvent A, et al. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the societe Francophone de greffe de moelle et de therapie cellulaire (SFGM-TC). *Bone Marrow Transplant.* 2017;52(5):678-82.
11. Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, Wollmer E, Wasch R, Bornhauser M, Berg T, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). *J Clin Oncol.* 2020;38(26):2993-3002.
12. Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. *Biol Blood Marrow Transplant.* 2014;20(12):2042-8.
13. Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, et al. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic

- haematopoietic cell transplantation-Immune signature correlates with response. *Br J Haematol.* 2023;203(2):264-81.
14. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. *N Engl J Med.* 2016;375(2):143-53.
  15. Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, et al. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. *Blood.* 2020;135(24):2182-91.
  16. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. *Blood.* 2009;113(7):1581-8.
  17. Penter L, Gohil SH, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg D, Hodi FS, Livak KJ, et al. Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. *Blood Adv.* 2021;5(22):4701-9.
  18. El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. *Nat Commun.* 2021;12(1):6436.
  19. Zhao P, Ni M, Ma D, Fang Q, Zhang Y, Li Y, Huang Y, Chen Y, Chai X, Zhan Y, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. *Ann Hematol.* 2022;101(1):119-30.
  20. Ho J, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Nunez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. *Blood.* 2022;140(10):1167-81.
  21. Zeiser R, Beelen DW, Bethge W, Bornhauser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, et al. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2019;25(4):e128-e40.
  22. Wherry EJ, and Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol.* 2015;15(8):486-99.
  23. Dixon KO, Tabaka M, Schramm MA, Xiao S, Tang R, Dionne D, Anderson AC, Rozenblatt-Rosen O, Regev A, and Kuchroo VK. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. *Nature.* 2021;595(7865):101-6.
  24. Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, and Ahmed R. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. *Annu Rev Med.* 2018;69(301-18).
  25. Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. *Cell Stem Cell.* 2010;7(6):708-17.
  26. Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, Niuro H, Yurino A, Miyawaki K, Takenaka K, et al. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. *Cell Stem Cell.* 2015;17(3):341-52.
  27. Dama P, Tang M, Fulton N, Kline J, and Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. *J Immunother Cancer.* 2019;7(1):175.
  28. Wei AH, Esteve J, Porkka K, Knapper S, Vey N, Scholl S, Garcia-Manero G, Wermke M, Janssen J, Traer E, et al. Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. *Blood.* 2020;136(Supplement 1):40-2.

29. Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. *Sci Transl Med.* 2018;10(429).
30. Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. *Nat Commun.* 2019;10(1):1065.
31. Duhén T, Duhén R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nat Commun.* 2018;9(1):2724.
32. Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B, Guo J, Wang S, Zhou P, Zhang H, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells. *Gut.* 2021;70(10):1965-77.
33. Tallon de Lara P, Castanon H, Vermeer M, Nunez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H, Movahedian Attar F, et al. CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer. *Nat Commun.* 2021;12(1):769.
34. Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, and Li J. The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. *Mol Ther.* 2021;29(5):1794-807.
35. Arguello RJ, Combes AJ, Char R, Gigan JP, Baaziz AI, Bousiquot E, Camosseto V, Samad B, Tsui J, Yan P, et al. SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution. *Cell Metab.* 2020;32(6):1063-75 e7.
36. Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. *Cell.* 2023;186(7):1432-47 e17.
37. Gungabeesoon J, Gort-Freitas NA, Kiss M, Bolli E, Messemaker M, Siwicki M, Hicham M, Bill R, Koch P, Cianciaruso C, et al. A neutrophil response linked to tumor control in immunotherapy. *Cell.* 2023;186(7):1448-64 e20.
38. Dahling S, Mansilla AM, Knopper K, Grafen A, Utzschneider DT, Ugur M, Whitney PG, Bachem A, Arampatzi P, Imdahl F, et al. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. *Immunity.* 2022;55(4):656-70 e8.
39. Raghu D, Xue HH, and Mielke LA. Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1. *Trends Immunol.* 2019;40(12):1149-62.
40. Sekine T, Perez-Potti A, Nguyen S, Gorin JB, Wu VH, Gostick E, Llewellyn-Lacey S, Hammer Q, Falck-Jones S, Vangeti S, et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. *Sci Immunol.* 2020;5(49).
41. Seo H, Chen J, Gonzalez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, Lopez-Moyado IF, Georges RO, Zhang W, Onodera A, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion. *Proc Natl Acad Sci U S A.* 2019;116(25):12410-5.
42. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell.* 2018;175(4):998-1013 e20.
43. Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat Immunol.* 2019;20(3):326-36.
44. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V, Ngiow SF, Khan O, Huang YJ, et al. Developmental Relationships of Four Exhausted CD8(+) T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. *Immunity.* 2020;52(5):825-41 e8.

45. Gattinoni L, Ji Y, and Restifo NP. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. *Clin Cancer Res.* 2010;16(19):4695-701.
46. Ma J, Wang R, Fang X, and Sun Z. beta-catenin/TCF-1 pathway in T cell development and differentiation. *J Neuroimmune Pharmacol.* 2012;7(4):750-62.
47. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. *Nat Med.* 2009;15(7):808-13.
48. Gullicksrud JA, Li F, Xing S, Zeng Z, Peng W, Badovinac VP, Harty JT, and Xue HH. Differential Requirements for Tcf1 Long Isoforms in CD8(+) and CD4(+) T Cell Responses to Acute Viral Infection. *J Immunol.* 2017;199(3):911-9.
49. Mammadli M, Suo L, Sen JM, and Karimi M. TCF-1 Is Required for CD4 T Cell Persistence Functions during Alloimmunity. *Int J Mol Sci.* 2023;24(5).
50. van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, Verga JA, Stephansky J, Pastika TJ, Lombardi Story J, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. *Cell.* 2019;176(6):1265-81 e24.
51. Beneyto-Calabuig S, Merbach AK, Kniffka JA, Antes M, Szu-Tu C, Rohde C, Waclawiczek A, Stelmach P, Grassle S, Pervan P, et al. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia. *Cell Stem Cell.* 2023;30(5):706-21 e8.
52. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. *Nat Commun.* 2021;12(1):6071.
53. Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, et al. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. *Blood.* 2023;141(15):1817-30.
54. Huo Y, Wu L, Pang A, Li Q, Hong F, Zhu C, Yang Z, Dai W, Zheng Y, Meng Q, et al. Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation. *Sci Immunol.* 2023;8(81):eabn6429.
55. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. Integrated analysis of multimodal single-cell data. *Cell.* 2021;184(13):3573-87 e29.
56. Huuhtanen J, Brück O, Peltonen K, Kreutzman A, Dufva O, Kankainen M, Ilander M, Lähteenmäki H, Kasanen T, Klievink J, et al. Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS. *Blood.* 2021;138(Supplement 1):801-.
57. Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D, et al. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. *Oncoimmunology.* 2021;10(1):1889822.
58. National Cancer Institute: TARGET Data Matrix. <https://targetncinihgov/dataMatrix/>.
59. Auletta JJ, Kou J., Chen M., Shaw B.E. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. *CIBMTR US summary slides.* 2021.
60. Zhou M, Sacirbegovic F, Zhao K, Rosenberger S, and Shlomchik WD. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. *Nat Commun.* 2020;11(1):4227.
61. Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, and Lanier LL. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. *Blood.* 2012;119(16):3734-43.
62. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. *Blood.* 2012;119(13):3064-72.



63. da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, and Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. *Cancer Immunol Res.* 2014;2(5):410-22.
64. So EC, Khaladj-Ghom A, Ji Y, Amin J, Song Y, Burch E, Zhou H, Sun H, Chen S, Bentzen S, et al. NK cell expression of Tim-3: First impressions matter. *Immunobiology.* 2019;224(3):362-70.
65. Xin A, Masson F, Liao Y, Preston S, Guan T, Gloury R, Olshansky M, Lin JX, Li P, Speed TP, et al. A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet. *Nat Immunol.* 2016;17(4):422-32.
66. Wolf Y, Anderson AC, and Kuchroo VK. TIM3 comes of age as an inhibitory receptor. *Nat Rev Immunol.* 2020;20(3):173-85.
67. Veenstra RG, Taylor PA, Zhou Q, Panoskaltis-Mortari A, Hirashima M, Flynn R, Liu D, Anderson AC, Strom TB, Kuchroo VK, et al. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. *Blood.* 2012;120(3):682-90.
68. Marijt E, Wafelman A, van der Hoorn M, van Bergen C, Bongaerts R, van Luxemburg-Heijs S, van den Muijsenberg J, Wolbers JO, van der Werff N, Willemze R, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. *Haematologica.* 2007;92(1):72-80.
69. Zeiser R, Devillier R, Mico' MC, Valcarcel D, Call S, Niederwieser C, Nourry C, Xu Y, Medts T, Guichard N, et al. TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study. *Blood.* 2023;142(Supplement 1):59-.

## Figure legends

### Figure 1: TIM-3 inhibition enhances GVL effects in different AML models

Murine primary HSCs (C57BL/6) were transduced with the indicated oncogenes or gene fusions. RNA expression of **(A)** *Lgals9* and **(B)** *Ceacam1* was determined by qPCR. Gene expression was normalized to *Hprt*. Fold change was calculated in comparison to empty vector (dotted line). Results represent mean  $\pm$  SEM from 3 independent experiments. P-values were calculated using Kruskal-Wallis One-Way ANOVA multiple comparisons test. **(C-E)** Kaplan-Meier plots showing mouse survival in the indicated groups. BALB/c recipient mice were injected *i.v.* with  $7 \times 10^4$  oncogene-transduced HSCs  $5 \times 10^6$  allogeneic BM and/or Tc when indicated. All mice were treated *i.p.* with isotype Ab or anti-TIM-3 Ab as indicated. P-values were calculated using 2-sided Mantel-Cox test. **(F-I)** RNA expression of **(F)** *Havcr2*, **(G)** *Lgals9* **(H)** *Ceacam1* and **(I)** *Hmgb1* in WEHI-3B (n=13) and in FLT3-ITD MLL-PTD cells (n=6) was analyzed by qPCR. Gene expression is shown as percent of *Hprt*. P-values were calculated using an unpaired Student's t-test. **(J-K)** Kaplan-Meier plot showing mouse survival in the indicated groups. Recipient mice were injected *i.v.* with FLT3-ITD MLL-PTD **(J)** or WEHI-3B cells **(K)** and  $5 \times 10^6$  allogeneic BM and/or Tc and treated with either isotype Ab or anti-TIM-3 Ab, as indicated. P-value was calculated using 2-sided Mantel-Cox test. **(K)** Kaplan-Meier plots showing mouse survival in the indicated groups. BALB/c recipient mice were injected with WEHI-3B cells and  $5 \times 10^6$  allogeneic BM and Tc and treated with isotype Ab (n=10) or anti-TIM-3 Ab (n=10). Results represent two independent experiments. P-value was calculated using 2-sided Mantel-Cox test. **(L)** Results show mean  $\pm$  SEM of CD45<sup>+</sup> H-2Kb<sup>+</sup> cells frequency in the BM at day 23 after allo-HCT. C57BL/6 recipient mice were injected with FLT3-ITD MLL-PTD cells and allogeneic BM and/or Tc, and treated with isotype Ab (n=10) or anti-TIM-3 Ab (n=10). P-values were calculated using one-way Anova followed by Tukey's multiple comparisons test.

### Figure 2:

#### Anti-TIM-3 Ab treatment after allo-HCT reduces Tc exhaustion, increases glycolytic capacity of Tc and induces changes in myeloid subsets

**(A-B)** BALB/c recipient mice were injected with WEHI-3B cells,  $5 \times 10^6$  allogeneic BM and Tc and treated with isotype (n=12) or anti-TIM-3 Ab (n=13). The proportion of TIM-3<sup>+</sup>PD-1<sup>+</sup> cells within CD4<sup>+</sup> **(A)** or CD8<sup>+</sup> Tc **(B)** in the indicated organ was determined by FC at d23. Results represent mean  $\pm$  SEM and P-values were calculated using Mann-Whitney U test. **(C-N)** C57BL/6 recipient mice were injected with FLT3-ITD MLL-PTD cells,  $5 \times 10^6$  allogeneic BM and Tc and treated with isotype Ab or anti-TIM-3 Ab. Donor Tc were isolated from the spleen at day 23 post-allo-HCT. **(C)** Analysis using high-resolution spectral-FC allows UMAP visualization of the immune landscape. **(D-E)** Scaled expression of 25 phenotypic or functional

markers using the FlowSOM algorithm among 6 CD4<sup>+</sup> or 4 CD8<sup>+</sup> Tc subsets. Log fold change of isotype Ab (n=6) compared to anti-TIM-3 Ab (n=8) treatment is shown (blue color depicts higher expression in isotype, red color higher expression in anti-TIM-3). Differentially expressed proteins with P-value < 0.05 tested with moderated t-test of limma are presented. **(F-G)** Glycolytic capacity of Tc subsets at day 23 assessed by FC-based single-cell metabolism. Results show mean ± SEM of n=9 biological replicates for each condition. P-values were calculated using Mann-Whitney U test. **(H)** Volcano plot of 1249 metabolic features from non-targeted LC-MS analysis. Features that were identified as members of the KEGG module “glycolysis” were highlighted. Results show n=5 isotype and n=8 anti-TIM-3-treated mice. (DHAP: dihydroxyacetonephosphate, PGA: phosphoglyceric acid, PEP: phosphoenolpyruvate, G6P: glucose-6-phosphate, F6P: fructose-6-phosphate, FBP: fructose-bisphosphate). **(I)** Analysis using high-resolution spectral-FC allows UMAP visualization of immune cells. **(J)** Proportion of each cell subset among total cells in the respective condition. Proportion of leukemia blasts **(K)**, neutrophils **(L)**, cDC1s **(M)**, and macrophages **(N)** among total cells (%). P-values were calculated using unpaired Student’s t-test.

### **Figure 3: Anti-TIM-3 Ab treatment reduces Tc exhaustion *in vitro***

**(A-G)** Tc isolated from spleens (C57BL/6 mice) were continuously exposed to TCR stimulation ( $\alpha$ CD3/CD28 beads) *in vitro* for 14 days in RPMI medium supplemented with 10% FBS, 1% penicillin / streptomycin and 30U/mL of mIL-2 to obtain highly activated/exhausted Tc. Cells were treated every second day with 10  $\mu$ g/mL of isotype or anti-TIM-3 Ab. **(A)** Representative plots showing the proportion of TIM-3<sup>+</sup>PD-1<sup>+</sup> cells among viable CD4<sup>+</sup> and CD8<sup>+</sup> Tc treated with isotype or anti-TIM-3 was determined by FC. Relative TIM-3 protein expression in CD4<sup>+</sup> Tc **(B)** and in CD8<sup>+</sup> Tc **(C)** based on MFI for n=6 replicates for each condition. P-values were calculated using Wilcoxon signed-rank test. **(D-E)** Proportion (%) of TIM-3<sup>+</sup>PD-1<sup>+</sup> within all CD4<sup>+</sup> Tc **(D)** and within all CD8<sup>+</sup> Tc **(E)**. Results represent mean ± SEM for isotype Ab (n=6) and anti-TIM-3 Ab (n=6) are shown. P-values were calculated using Mann-Whitney U test. **(F)** Relative TOX protein expression as relative MFI determined by FC in CD4<sup>+</sup> Tc and **(G)** Representative FC staining of TOX expression in CD4<sup>+</sup> Tc for both isotype Ab (blue line) and anti-TIM-3 Ab treatment (red line). **(H)** Relative TOX protein expression as relative MFI determined by FC in CD8<sup>+</sup> Tc and **(I)** Representative staining of TOX expression in CD8<sup>+</sup> Tc for both isotype Ab (blue line) and anti-TIM-3 Ab treatment (red line). Results represent mean ± SEM of n=5 isotype treatment or n=5 anti-TIM-3 treatment. P-values were calculated using Wilcoxon signed-rank test.

### **Figure 4: Genetic TIM-3 deletion in CD8<sup>+</sup> Tc enhances Tc activation, proliferation and IFN- $\gamma$ production as well as GVL effects**

**(A-E)** Tc labeled with CTV (“responders”, C57BL/6) were co-cultured for 6 days with allogeneic non-CD3 cells (“stimulators”, BALB/c). Responder cells were isolated from mice carrying TIM-3 deletion in CD8<sup>+</sup> Tc (*Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>*) as described in (23). **(A)** Proportion of proliferative cells was quantified at day 6 as the percentage of CTV<sup>low</sup> cells in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* CD3<sup>+</sup> responder Tc. **(B)** CD25 expression in proliferative CD3<sup>+</sup> responder cells were quantified at day 6 by FC. **(C)** Representative staining of CD25 expression in *Havcr2<sup>fl/fl</sup>* (blue line) and in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* cells (red line). **(D)** CD69 expression in proliferative CD3<sup>+</sup> responder cells were quantified at day 6 by FC. **(E)** Representative staining of CD69 expression in *Havcr2<sup>fl/fl</sup>* (blue line) and in *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* cells (red line). **(F-G)** Production of IFN- $\gamma$  in the supernatant of the culture analyzed at the indicated time points by ELISA. P-values were calculated using an unpaired Student’s t-test. **(H-I)** Kaplan-Meier plots showing survival of mice in the indicated groups. BALB/c recipient mice were injected i.v. with WEHI-3B AML cells (BALB/c background) and **(H)** allogeneic *Havcr2<sup>fl/fl</sup>* (n=10) or *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* (n=10) BM and Tc or **(I)** allogeneic *Havcr2<sup>fl/fl</sup>* (n=10) or *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* (n=10) BM and Tc. Data were pooled from two independent experiments and P-values were calculated using the 2-sided Mantel-Cox test. **(J)** Percentage of specific lysis of  $\alpha$ CD3/CD28 activated Tc isolated from *Havcr2<sup>cko</sup>* mice in contact with WEHI-3B cells. E:T (effector [Tc] to target [WEHI-3B cell]) ratio was titrated between 5:1 and 1:1 as indicated. Individual values are shown and mean  $\pm$  SD of *Havcr2<sup>fl/fl</sup>* (n=6) or *Havcr2<sup>fl/fl</sup>;Cd4<sup>cre/+</sup>* (n=6). P-values were calculated using a two-way Anova followed by Sidak’s multiple comparisons test.

### Figure 5: Deletion of TIM-3 in CD8<sup>+</sup> Tc leads to T<sub>PEX</sub> expansion

**(A-E)** BALB/c recipient mice were injected i.v. with WEHI-3B AML cells (BALB/c background) and 5x10<sup>6</sup> allogeneic *Havcr2<sup>fl/fl</sup>* (n=2) and *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* (n=2) BM and Tc. Tc were isolated at day 23 and stained with an oligo-tagged H-2Kb (donor) Ab allowing scRNA-seq analysis of FACS sorted donor Tc. **(A)** UMAP visualization of 10 clusters of CD8<sup>+</sup> Tc. **(B)** Feature plots showing the expression level of different marker genes relevant for the characterization of the respective cluster. **(C)** Bar diagram representing the frequency of the different CD8<sup>+</sup> Tc clusters. Adjusted P-values were calculated using Fisher’s test. **(D)** Expression level of key genes differentially expressed in Tc from AML-bearing mice receiving *Havcr2<sup>fl/fl</sup>* (left) and *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* (right) BM/Tc in cluster 6. **(E)** Score of the functional signature enriched in Tc from AML-bearing mice receiving *Havcr2<sup>fl/fl</sup>;E8I<sup>cre/+</sup>* BM/Tc compared to *Havcr2<sup>fl/fl</sup>* BM/Tc in cluster 7. Gene expression analysis of genes within the “memory precursor” signature. (Tem: effector memory Tc; Teff: effector Tc).

### Figure 6: Anti-TIM-3 treatment leads to recall immunity against AML cells without inducing aGVHD

**(A)** Kaplan-Meier plot showing mouse survival in the indicated groups. C57BL/6 recipient mice were injected with FLT3-ITD MLL-PTD AML cells and  $5 \times 10^6$  allogeneic BM. At day 2, mice received adoptive transfer of  $3 \times 10^5$  allogeneic donor Tc. Allogeneic Tc were isolated on day 15 from FLT3-ITD MLL-PTD AML-bearing mice, which received allogeneic BM/Tc and were treated with isotype (n=14) or anti-TIM-3 (n=14) Ab. **(B-D)** The scatter plots show the histopathological aGVHD severity in the indicated groups. BALB/c recipient mice were injected *i.v.* with  $5 \times 10^6$  allogeneic BM and  $4 \times 10^5$  allogeneic Tc. From day 1 to day 5, mice were treated (150 $\mu$ g, *i.p.*) with anti-TIM-3 / isotype, anti-PD-1 / isotype or anti-CTLA-4 / isotype. aGVHD histological scores were determined on liver, SI, and colon at day 7 for the different groups. Results show mean  $\pm$  SEM from 2 independent experiments. P-values were calculated using an unpaired Student's t-test.

### **Figure 7: Anti-human TIM-3 Ab sabatolimab enhances the GVL effect**


**(A)** Kaplan-Meier plots showing mouse survival in the indicated groups. *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* recipient mice were injected *i.v.* with human-derived MOLM-13<sup>luc+</sup> AML cells and human CD3<sup>+</sup> Tc (from HLA non-matched healthy donors), and treated with vehicle (n=10) or human anti-TIM-3 (n=10). Results show 3 independent experiments and P-value was calculated using 2-sided Mantel-Cox test. **(B)** Representative images of Bioluminescence imaging (BLI) of MOLM-13<sup>luc+</sup> AML-bearing *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* recipient mice 21 days after injection of AML cells, following human Tc injection and vehicle or human anti-TIM-3 Ab treatment. **(C)** BLI signal quantification shows the expansion of AML cells over time. Results show mean  $\pm$  SEM from 3 independent experiments using 3 different healthy T cell donors. P-values were calculated using 2-sided Mann-Whitney U test. **(D-E)** Kaplan-Meier plots showing mouse survival in the indicated groups. *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* recipient mice were injected *i.v.* with CD3 depleted primary AML cells (from PB at primary diagnosis) and treated with vehicle (n=3) or human anti-TIM-3 (n=3). Each survival curve represents one individual AML donor patient. P-values were calculated using 2-sided Mantel-Cox test. **(F)** Representative Western blots showing the inhibition of phospho-FLT3 (Tyr589/591) upon treatment with 3 different FLT3 inhibitors and loading control ( $\beta$ -actin) in MOLM-13 cells (FLT3-ITD). **(G)** Gal-9 **(H)** CEACAM1 and **(I)** TIM-3 protein expression as relative MFI was determined by FC upon the treatment with the indicated FLT3 inhibitors, in FLT3-ITD-positive human cell line (MOLM-13) or FLT3 WT human cell line (Kasumi-1). Fold change is calculated in comparison to the treatment using DMSO (control treatment). Results represent mean  $\pm$  SEM from 8 independent experiments using MOLM-13 cells and n=5 independent experiments using Kasumi-1 cells. P-values were calculated using ordinary one-way Anova.

### Figure 8: Expression of TIM-3 and its ligands in human primary samples


**(A)** Overview of UMAP embedding colored by 27 projected cell types of 574,502 scRNA-seq profiles from van Galen et al., (50) (n=20,362), Abbas et al., (52) (n=127,027), Huo et al., (54) (n=20,385), Beneyto-Calabuig et al., (51) (n=101,767) and Penter et al., (17) (n=304,961). Major cell types are highlighted. **(B)** Scaled gene expression of *HAVCR2*, *CEACAM1*, *HMGB1*, *LGALS9* and *PTDSS1* across AML BM scRNA-seq profiles. AML BM cases include newly diagnosed and relapsed disease with or without allo-HCT. **(C)** Proportion of TIM-3<sup>+</sup> cells of all NK cells across normal and AML BM datasets. **(D)** Heatmap generated from scRNA-seq profiles from van Galen et al., (50) showing expression of *HAVCR2*, *LGALS9* and *HMGB1* in normal hematopoiesis and AML cell types of patients at diagnosis of AML. **(E)** Expression of *HAVCR2*, *LGALS9*, *CEACAM1* and *HMGB1* in human AML cells determined by bulk RNA-seq. AML cells were isolated from patients with AML relapse after allo-HCT at multiple transplant centers. **(F)** Probability of survival stratified according to “High” versus “Low” *HAVCR2* gene expression in AML BM at diagnosis within the Target-AML cohort (58). RNAseq data was derived from the GenomicDataCommons (GDC) library. Gene expression more than one standard deviation above mean was defined as high expression.

# Figure 1


**A**



**B**




**C**




- AML (FLT3-ITD) + allo-HCT + isotype Ab (n=15)
- AML (FLT3-ITD) + allo-HCT + anti-TIM-3 Ab (n=15)
- AML (FLT3-ITD) + allo-HCT/Tc + isotype Ab (n=15)
- AML (FLT3-ITD) + allo-HCT/Tc + anti-TIM-3 Ab (n=21)

**D**




- AML (FIP1L1-PDGFR $\alpha$ ) + allo-HCT + isotype Ab (n=15)
- AML (FIP1L1-PDGFR $\alpha$ ) + allo-HCT + anti-TIM-3 Ab (n=15)
- AML (FIP1L1-PDGFR $\alpha$ ) + allo-HCT/Tc + isotype Ab (n=15)
- AML (FIP1L1-PDGFR $\alpha$ ) + allo-HCT/Tc + anti-TIM-3 Ab (n=21)

**E**




- AML (ckit-D816V) + allo-HCT + isotype Ab (n=8)
- AML (ckit-D816V) + allo-HCT + anti-TIM-3 Ab (n=10)
- AML (ckit-D816V) + allo-HCT/Tc + isotype Ab (n=10)
- AML (ckit-D816V) + allo-HCT/Tc + anti-TIM-3 Ab (n=10)


**F**




**G**




**H**



**I**




**J**




- AML (FLT3-ITD MLL-PTD) + allo-HCT + isotype Ab (n=5)
- AML (FLT3-ITD MLL-PTD) + allo-HCT + anti-TIM-3 Ab (n=5)
- AML (FLT3-ITD MLL-PTD) + allo-HCT/Tc + isotype Ab (n=5)
- AML (FLT3-ITD MLL-PTD) + allo-HCT/Tc + anti-TIM-3 Ab (n=5)

**K**



- AML (WEHI-3B) + allo-HCT/Tc + isotype Ab (n=10)
- AML (WEHI-3B) + allo-HCT/Tc + anti-TIM-3 Ab (n=10)

**L**



# Figure 2








Figure 3




# Figure 4




# Figure 5


**A**




**B**




**C**



**D**




**E**




# Figure 6

A




- AML (FLT3-ITD MLL-PTD) + allo-HCT + Tc from isotype-treated BM/Tc mice (n=14)
- AML (FLT3-ITD MLL-PTD) + allo-HCT + Tc from anti-TIM-3-treated BM/Tc mice (n=14)


B



C



D



# Figure 7

